

Latent tuberculosis infection

Updated and
consolidated
guidelines for
programmatic
management

Latent tuberculosis infection

Updated and consolidated guidelines for
programmatic management



**World Health
Organization**

© **World Health Organization 2018**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Contents

Acknowledgements	v
Declaration and management of conflicts of interest	vii
Abbreviations	ix
Definitions	x
Executive summary	1
1. Introduction	5
2. Identification of populations for testing and treatment of latent tuberculosis infection	9
3. Algorithms for ruling out active tuberculosis disease	14
4. Testing for latent tuberculosis infection	21
5. Treatment options for latent tuberculosis infection	23
6. Preventive treatment for contacts of patients with multidrug-resistant tuberculosis	28
7. Issues in implementation	30
8. Research priorities	32
9. References	34
Annex 1. GRADE profile tables for new recommendations	39
Annex 2. Evidence-to-Decision and GRADE tables (online at www.who.int/tb)	
Annex 3. Survey on the values and preferences for the management of latent tuberculosis infection (online at www.who.int/tb)	

Acknowledgements

Overall coordination and writing of the guidelines

Yohhei Hamada and Haileyesus Getahun coordinated the development and writing of the guidelines under the overall direction of Mario Raviglione.

WHO steering group

Andrei Dadu (TB and M/XDR-TB Programme, WHO Regional Office for Europe); Meg Doherty (HIV department, WHO); Dennis Falzon (Global TB Programme, WHO); Nathan Ford (HIV department, WHO); Haileyesus Getahun (Global TB Programme, WHO); Christopher Gilpin (Global TB Programme, WHO); Malgorzata Grzemska (Global TB Programme, WHO); Yohhei Hamada (Global TB Programme, WHO); Andreas Reis (Information, Evidence and Research, WHO); Wilson Were (Department of Maternal, Newborn, Child and Adolescent Health, WHO).

Co-chairs of the WHO Guidelines Development Group

Alberto Matteelli (University of Brescia, WHO Collaborative Centre for TB/HIV and TB Elimination, Italy) and Nandi Siegfried (independent clinical epidemiologist, South Africa)

GRADE methodologist for the WHO Guidelines Development Group

Nandi Siegfried (independent clinical epidemiologist, South Africa).

Members of WHO Guidelines Development Group

Si Thu Aung (National TB Programme, Department of Public Health, Ministry of Health, Myanmar); Rolando Cedillos (Service of Infectology and Integrated Programme for STI/HIV/AIDS, El Salvador); Richard Chaisson (Center for TB Research, Johns Hopkins University, United States of America); Padmapriyadarsini Chandrasekaran (National Institute for Research in Tuberculosis, India); Lucy Chesire (TB Advocacy Consortium, Kenya); Betina Durovni (Federal University of Rio de Janeiro, Brazil); Diana Gibb (Medical Research Council, United Kingdom of Great Britain and Northern Ireland); Stephen Graham (Centre for International Child Health, University of Melbourne, Australia); Sally Hargreaves (Imperial College London, United Kingdom); Diane Havlir (University of California, USA); Nguyen van Hung (National Lung Hospital, Viet Nam); Mohammed Al Lawati (Consultant Physician, Oman); Alberto Matteelli (University of Brescia, WHO Collaborative Centre for TB/HIV and TB Elimination, Italy); Lindiwe Mvusi (National Department of Health, South Africa); Nadia Ismail Abu Sabrah (consultant TB physician and epidemiologist, Jordan); Marieke van der Werf (European Centre for Disease Prevention and Control, Sweden); Wim Vandeveld (Global TB Community Advisory Board, South Africa); Irina Vasilyeva (Ministry of Health, Russian Federation)

Observers

Anand Date (Centers for Disease Control and Prevention, USA); Ya Diul Mukadi (US Agency for International Development [USAID], USA).

Systematic reviewers

Yalemzewed Assefa (University of Queensland, Australia); Yibeltal Assefa (University of Queensland, Australia); Ioana Diana Olaru (Borstel Research Centre, Germany); Darshini Govindasamy (South African Medical Research Council, South Africa); Yohhei Hamada (Global TB Programme, WHO), Sandra Kik (KNCV Tuberculosis Foundation, Netherlands); Katharina Kranzer (London School of Hygiene and Tropical Medicine, United Kingdom); Johnny Lujan (Global TB Programme, WHO); Molebogeng Xheedha Rangaka (University College London, United Kingdom); Karl Schenkel (Global TB Programme, WHO); Solomon Woldeyohannes (University of Queensland, Australia).

Peer reviewers

Sevim Ahmedov (USAID, USA); Taye Tolera Balcha (Armauer Hansen Research Institute, Ethiopia); Amy Bloom (USAID, USA); Anne Detjen (UNICEF); Christine Ho (Centers for Disease Control and Prevention, USA); Sundari Mase (WHO Country Office, India); Michael Kimerling (KNCV Tuberculosis Foundation, Netherlands); Giovanni Battista Migliori (WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Italy); Zelalem Temesgen (Mayo Clinic, USA).

Other contributors

Liani Smit (University of Stellenbosch and Western Cape Department of Health, South Africa) provided input for the survey of values and preferences; Enrico Girardi and Monica Sanè Schepisi (Istituto Nazionale Malattie Infettive L. Spallanzani, Italy) shared results from an updated systematic review of the cost-effectiveness of testing and treatment for latent tuberculosis.

WHO staff and consultants

Global TB Programme: Annabel Baddeley, Ernesto Jaramillo, Avinash Kanchar, Knut Lönnroth, Kefas Samson, Karin Weyer

HIV department: Satvinder Singh

Financial support

Preparation of these guidelines was supported financially by the US Centers for Disease Control and Prevention, USAID and the Ministry of Health of the Republic of Korea.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_25997

